Indian Drug Plants Most Affected By U.S. Rule Cutting Compliance Time
This article was originally published in PharmAsia News
Executive Summary
Indian pharmaceutical plants are expected to be among those most affected by a new U.S. FDA rule cutting in half the grace period for drug makers to meet FDA standards